8-K: scPharmaceuticals Reports Q1 2024 Results, FUROSCIX Sales Rise Despite Cyberattack Impact

scPharmaceuticals announced its first quarter 2024 financial results, highlighting a significant increase in FUROSCIX revenue despite a cyberattack impacting doses filled.

Summary

• scPharmaceuticals reported a net FUROSCIX revenue of $6.1 million for the first quarter of 2024, a substantial increase compared to $2.1 million in the same period last year.
• The company experienced a 10% negative impact on doses filled due to the Change Healthcare cyberattack.
• Despite this, total FUROSCIX doses written increased by 28% sequentially to 17,376, and doses filled rose by 15% to 8,074.
• The number of unique prescribers increased by 29% to 2,184, and in-services completed rose to 2,938.
• The gross-to-net discount was 19% in Q1 2024, and is expected to increase to 30-35% by the end of the year.
• The company ended the quarter with $58.4 million in cash and cash equivalents.
• A pivotal pharmacokinetic study for an 80mg/1mL auto-injector was initiated, with a planned sNDA submission by the end of 2024.
• The sNDA for expanding the FUROSCIX indication to include NYHA Class IV heart failure patients is under FDA review, with a PDUFA date in August 2024.
• The company reported a net loss of $14.1 million for the quarter, compared to a net loss of $11.2 million in the first quarter of 2023.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with strong revenue growth and increasing market adoption of FUROSCIX. However, the net loss and expected increase in gross-to-net discounts temper the overall sentiment.

Positives

• FUROSCIX revenue showed strong growth, reaching $6.1 million in the first quarter of 2024.
• The number of FUROSCIX prescriptions and doses filled increased significantly, indicating growing market adoption.
• The company is progressing with its long-term growth initiatives, including the development of a new auto-injector and label expansion.
• The number of unique prescribers and in-services completed are increasing, suggesting growing acceptance of FUROSCIX among healthcare providers.
• The company has a solid cash position of $58.4 million.

Negatives

• The Change Healthcare cyberattack negatively impacted doses filled by an estimated 10%.
• The company reported a net loss of $14.1 million for the first quarter of 2024.
• The gross-to-net discount is expected to increase to 30-35% by the end of the year, which could impact future revenue.
• Operating expenses increased significantly compared to the same period last year.

Risks

• The company is dependent on the commercial success of FUROSCIX.
• There are risks related to obtaining regulatory approval for product candidates.
• The company faces risks related to manufacturing and supply of FUROSCIX.
• The company has a history of operating losses.
• Global economic factors and uncertainties could impact the company's operations.

Future Outlook

The company anticipates continued growth in FUROSCIX sales, driven by its commercial trajectory and long-term growth initiatives, including label expansion and the development of a new auto-injector. The gross-to-net discount is expected to increase over time, possibly reaching 30-35% by the end of the year.

Management Comments

• John Tucker, President and CEO, stated that the company sustained sales momentum despite the cyberattack and seasonality.
• Mr. Tucker noted that leading indicators suggest providers are increasingly comfortable prescribing FUROSCIX.
• Management believes that the current commercial trajectory and long-term growth initiatives form a solid foundation for future sales growth.

Industry Context

This announcement reflects the ongoing efforts of pharmaceutical companies to expand treatment options for heart failure patients. The focus on subcutaneous administration and the development of an auto-injector align with trends towards more convenient and patient-friendly drug delivery methods. The cyberattack impact highlights the vulnerability of healthcare systems to such events.

Comparison to Industry Standards

• The 28% sequential increase in FUROSCIX doses written is a positive sign, indicating strong market adoption compared to other new drug launches in the heart failure space.
• The 15% sequential increase in doses filled is also a positive indicator, although the 10% negative impact from the cyberattack suggests that the growth could have been higher.
• The gross-to-net discount of 19% is within the expected range for a newly launched product, but the projected increase to 30-35% by the end of the year is significant and will need to be monitored closely. This is similar to other specialty pharmaceutical products that have high initial discounts to gain market access.
• The company's cash position of $58.4 million is adequate for a company of this size, but they will need to manage their cash burn carefully as they continue to invest in R&D and commercialization. This is comparable to other small-cap biotech companies in the commercialization phase.

Stakeholder Impact

• Shareholders will be impacted by the financial results and the company's future prospects.
• Employees will be impacted by the company's performance and growth.
• Patients will benefit from the availability of FUROSCIX and the potential for expanded indications.
• Healthcare providers will be impacted by the increasing adoption of FUROSCIX.

Next Steps

• The company will continue to advance the development of the 80mg/1mL auto-injector.
• The company will await the FDA's decision on the sNDA for expanding the FUROSCIX indication to include NYHA Class IV heart failure patients.
• The company will continue to focus on commercializing FUROSCIX and expanding its market reach.
• The company will continue to progress contracting efforts with payers.

Key Dates

Keywords

FUROSCIX, scPharmaceuticals, Heart Failure, Subcutaneous Injection, Pharmaceuticals, FDA, Cyberattack, Revenue, Net Loss, Auto-injector